Inari Medical is expanding its regulatory affairs team to pursue the OUS markets to remain the global leader in venous clot removal that has developed three thrombectomy technology platforms for the treatment of venous thrombosis. Inari Medical forecasts 40% of their growth to be tied to OUS expansion, which makes this growth effort a key focus for Inari’s executive management and the public markets. Oh, and Inari Medical is named after a piece of sushi…inari sushi.
Prior to Inari Medical’s successful IPO in 2020, Inari was funded by prestigious venture capital firms, Gilde Healthcare, Versant Ventures, and U.S. Venture Partners, and then debuted as the best U.S. IPO of 2020. This year, Inari generated $235M in revenue in 1H 2023 with a 31% increase from 2022. We are hiring our Senior Manager, International Regulatory Affairs Leader that will initially focus on EMEA and APAC market expansion.
We have partnered with Keith Herbert, Senior Director of Regulatory Affairs, and Jayme Yamaguchi-Owens, Director of Regulatory Affairs, to hire our Senior Manager, International Regulatory Affairs. This position will lead a team of direct reports and support cross functional teams with submissions and additional regulatory documents for Class I, II, and III devices to international regulatory bodies.
Inari Medical, Inc. is a publicly traded medical device company dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism. Inari is focused on solutions that enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs. Inari has developed three novel mechanical thrombectomy technology platforms.
The FlowTriever System has FDA clearance for the treatment of pulmonary embolism and for thrombectomy in the peripheral vessels. The ClotTriever System has FDA clearance for thrombectomy in the peripheral vessels. The InThrill System has FDA clearance for small vein and AV thrombectomy. Inari was founded in 2013 as a spin-out of Inceptus Medical, a medical device incubator.
Company Overview
Lifeblood™ supports global MedTech Startups with Talent Acquisition and Fundraising Strategies. We build full-scale startup teams from Board and C-level executives to entry-level individual contributors and from early-stage R&D through multi-national commercialization phases.Approaching two decades of experience in the MedTech industry, our talent acquisition services and team-building efforts are the results of 2,000+ successful hires for 500+ companies in 6 continents. We have facilitated more than $220 million for MedTech startups with our fundraising strategies and global investor network.
People and money are the lifeblood capital of startups. Learn from our entrepreneurs and investors as we demystify raising and investing capital on our MedTech Money Podcast Series.